Test Catalog

Test ID: BCRFX    
BCR/ABL1 Qualitative Diagnostic Assay with Reflex to BCR/ABL1 p190 Quantitative Assay or BCR/ABL1 p210 Quantitative Assay, Varies

Useful For Suggests clinical disorders or settings where the test may be helpful

Diagnostic workup of patients with high probability of BCR-ABL1-positive hematopoietic neoplasms, predominantly chronic myeloid/myelogenous leukemia and acute lymphoblastic leukemia

 

When positive, the test identifies which specific mRNA fusion variant is present to guide selection of an appropriate monitoring assay.

Highlights

Following a positive BCR/ABL1 diagnostic RT-PCR result, a reflex test will be performed to provide a quantitative measurement of BCR/ABL1 mRNA transcript (either p190 or p210 types). Current National Comprehensive Cancer Network (NCCN) guidelines for chronic myeloid leukemia (CML), for example, indicate that the quantitative p210 mRNA transcript level be obtained at diagnosis. The reflex test establishes the initial patient diagnostic baseline level to assess response to therapy in follow-up samples.

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
B190RBCR/ABL1, p190, Quant, ReflexNo, (Bill Only); For Separate Testing: (Order BA190)No
B210RBCR/ABL1, p210, Quant, ReflexNo, (Bill Only); For Separate Testing: (Order BCRAB)No

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When a positive p210 or p190 BCR/ABL1 result is identified by the qualitative assay, a reflex test will then be performed at an additional charge to determine the quantitative transcript level of BCR/ABL1 mRNA. A positive p210 or p190 result will specifically trigger either quantitative p210 (B210R) or p190 (B190R) testing to provide a normalized percentage of transcript level. For the p210 target, the value is additionally defined using the International Scale (IS) convention. The results are released in an integrated report and provide a baseline quantitative transcript to monitor treatment response. If the initial qualitative testing is negative, or an alternate rare form of BCR/ABL1 is detected, then no reflex testing will be pursued and the initial results will be reported.

 

The following documents are available in Special Instructions:

-BCR/ABL1 Ordering Guide for Blood and Bone Marrow

-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation

-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Multiplex PCR

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

BCR/ABL1 Reflex, Qual/Quant

Aliases Lists additional common names for a test, as an aid in searching

Philadelphia Chromosome Ph1 Bone Marrow/Blood
Philadelphia
BCR/ABL
Chronic Myelogenous Leukemia (CML)
CML (Chronic myeloid/Myelogenous Leukemia)